Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
06 2022
Historique:
revised: 02 07 2021
received: 03 09 2020
accepted: 05 07 2021
pubmed: 27 7 2021
medline: 9 6 2022
entrez: 26 7 2021
Statut: ppublish

Résumé

The Models of Patient Engagement for Alzheimer's Disease (MOPEAD) project was conceived to explore innovative complementary strategies to uncover hidden prodromal and mild Alzheimer's disease (AD) dementia cases and to raise awareness both in the general public and among health professionals about the importance of early diagnosis. Four different strategies or RUNs were used: (a) a web-based (WB) prescreening tool, (2) an open house initiative (OHI), (3) a primary care-based protocol for early detection of cognitive decline (PC), and (4) a tertiary care-based pre-screening at diabetologist clinics (DC). A total of 1129 patients at high risk of having prodromal AD or dementia were identified of 2847 pre-screened individuals (39.7%). The corresponding proportion for the different initiatives were 36.8% (WB), 35.6% (OHI), 44.4% (PC), and 58.3% (DC). These four complementary pre-screening strategies were useful for identifying individuals at high risk of having prodromal or mild AD.

Identifiants

pubmed: 34310061
doi: 10.1002/alz.12441
pmc: PMC9290633
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1119-1127

Informations de copyright

© 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Références

J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
Lancet. 2018 Nov 17;392(10160):2214-2228
pubmed: 30314860
J Am Geriatr Soc. 2003 May;51(5 Suppl Dementia):S281-8
pubmed: 12801384
Lancet Neurol. 2016 Apr;15(5):455-532
pubmed: 26987701
J Neurol Neurosurg Psychiatry. 2009 Feb;80(2):133-9
pubmed: 18977819
Alzheimers Dement. 2022 Jun;18(6):1119-1127
pubmed: 34310061
Alzheimers Dement. 2021 Aug;17(8):1307-1316
pubmed: 33860599
J Alzheimers Dis. 2009;16(4):677-85
pubmed: 19387104
Lancet Diabetes Endocrinol. 2013 Nov;1(3):183-90
pubmed: 24622366
J Alzheimers Dis. 2020;76(1):33-40
pubmed: 32538856
J Alzheimers Dis. 2017;57(2):625-632
pubmed: 28269773
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S99-S107
pubmed: 26402087
Alzheimers Dement. 2019 Jun;15(6):828-839
pubmed: 31076376
Diabetes Care. 2013 Jun;36(6):1554-61
pubmed: 23275366
Neuropsychologia. 2001;39(11):1150-7
pubmed: 11527552
Neurology. 1988 Jun;38(6):900-3
pubmed: 3368071
Arch Gen Psychiatry. 2010 Apr;67(4):414-22
pubmed: 20368517

Auteurs

Mercè Boada (M)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain.

Adrián Rodrigo (A)

GMV SECURE E SOLUTIONS, Valencia, Spain.

Frank Jessen (F)

Department of Psychiatry, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

Bengt Wimblad (B)

Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
Theme Aging, Karolinska Univ Hospital, Stockholm, Sweden.

Milica G Kramberger (MG)

Department of Neurology, University Medical Center Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Pieter Jelle Visser (PJ)

Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.

Rafael Simó (R)

Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas. Instituto de Salud Carlos III, Spain.

Octavio Rodríguez-Gomez (O)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.

Andreea Ciudin (A)

Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas. Instituto de Salud Carlos III, Spain.

Jean Georges (J)

Alzheimer Europe, Luxembourg.

Annete Dumas (A)

ASDM Consulting, Brussels, Belgium.

Peggy Maguire (P)

European Institute of Women's Health, Dublin, Ireland.

David Krivec (D)

Zdruzenje Spomincica, Ljubljana, Slovenia.

Anders Wimo (A)

Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.

Sergi Valero (S)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain.

Montserrat Alegret (M)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain.

Laura Jamilis (L)

GMV SECURE E SOLUTIONS, Valencia, Spain.

Marissa Zwan (M)

Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.

Lena Sannemann (L)

Department of Psychiatry, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

Jordi Arrufat (J)

EAP Sarrià-Vallvidrera-Les Planes, Barcelona, Spain.

Erik Stomrud (E)

Clinical Memory Research Unit, Lund University, Malmö, Sweden.
Emmaboda Health Centre, Region Kalmar County, Emmaboda, Sweden.

Gunilla Johansson (G)

Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.

Craig Shering (C)

AstraZeneca, Waltham, Massachusetts, USA.

Bridget Glaysher (B)

Modus Research and Innovation Limited, Dundee, Scotland.

Neil Stewart (N)

Modus Research and Innovation Limited, Dundee, Scotland.

Mark Belger (M)

Eli Lilly and Company (Lilly UK), Surrey, UK.

Fatima Iradier (F)

Eli Lilly and Company, Spain.

Laura Campo (L)

Eli Lilly and Company, Firenze, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH